PT  - JOURNAL ARTICLE
AU  - Edelstein, Michael
AU  - Obi, Chinelo
AU  - Chand, Meera
AU  - Hopkins, Susan
AU  - Brown, Kevin
AU  - Ramsay, Mary
TI  - SARS-CoV-2 infection in London, England: Impact of lockdown on community point-prevalence, March-May 2020
AID  - 10.1101/2020.05.21.20109017
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.21.20109017
4099  - http://medrxiv.org/content/early/2020/05/25/2020.05.21.20109017.short
4100  - http://medrxiv.org/content/early/2020/05/25/2020.05.21.20109017.full
AB  - COVID-19 point prevalence PCR community testing allows disease burden estimation. In a sample of London residents, point prevalence decreased from 2.2% (95%CI 1.4;3.5) in early April (reflecting infection around lockdown implementation) to 0.2% (95%CI 0.03-1.6) in early May (reflecting infection 3-5 weeks into lockdown). Extrapolation from reports of confirmed cases suggest that 5-7.6% of total infections were confirmed by testing during this period. These data complement seroprevalence surveys improving the understanding of transmission in London.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthis study was conducted as part of PHE routine surveillance activities. No specific funding was obtainedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics statement Ethics approval for inviting participants for self-swabbing was obtained when Flusurvey was initially set up in 2008/9, and each participant was individually re-consented. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall available data are included in the manuscript